Anti-Argonaute Antibodies for the Diagnosis of Sensory Neuronopathies
- Conditions
- Autoimmune Diseases
- Interventions
- Diagnostic Test: Diagnosis of sensitive neuronopathy - phase 1Diagnostic Test: Diagnosis of sensitive neuronopathy - phase 2Other: Comparison with Chi2 methodOther: Comparison of data with parametric Test (T-test)Other: Comparison of data with non-parametric test (ANNOVA)
- Registration Number
- NCT05966350
- Brief Summary
Argonaute (AGO) proteins have been described as the target of antibodies in several autoimmune diseases including Sjögren Syndrome (SS). Sensory neuronopathies (SNN) are disorders affecting neurons in the dorsal root ganglia that may depend on an inflammatory process. However, identifying these cases needs the availability of specific biomarkers. The aim of this study is to test the prevalence of anti-AGO antibodies in a population of patients with Sensory neuronopathies (SNN) with and without associated autoimmune disease in comparison with other peripheral neuropathies to determine how anti-AGO antibodies may help the identification of potentially dysimmune Sensory neuronopathies (SNN).
- Detailed Description
Sensory neuronopathies (SNN) are rare and debilitating diseases that fall under several etiologies. Among them, dysimmune forms are the most frequent but very difficult to identify when they do not occur in the context of associated systemic dysimmune disease (Sjögren Syndrome (SS) syndrome) because only a biopsy of the epiphytically unthinkable posterior spinal node would support the diagnosis. It is therefore necessary to have diagnostic biological markers of these forms to consider rapid treatment before irreversible neuronal degeneration.Using a protein-array technique, it has been showed that anti-FGFR3 antibodies was one of these markers and that it was associated with a clinical picture that differentiated from Sensory neuronopathies (SNN) without this antibody. Protein-array also allowed to identify another potentially interesting antibody for the diagnosis of Sensitive neuronopathies (NNS). This antibody recognizes the AGO1 protein. Anti-AGO1 antibodies have been described in association with system autoimmune diseases and in particular lupus but not in neurological diseases and more particularly in Sensory neuronopathies (SNN). The study want to validate the diagnostic interest of these antibodies by testing the collection of serums performed for studies on the anti-FGFR3 antibody and including patients with Sensory neuronopathies (SNN) and as controls of patients with another form of neuropathy and subjects with systemic autoimmune disease without peripheral neuropathy.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 630
- Patients with sensory neuropathy
- Patient not tested for anti-AGO antibody
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Sensory neuronopathies (SNN) Diagnosis of sensitive neuronopathy - phase 1 Patients with Sensory neuronopathies (SNN) will be included. Sensory neuronopathies (SNN) Comparison with Chi2 method Patients with Sensory neuronopathies (SNN) will be included. Sensory neuronopathies (SNN) Comparison of data with non-parametric test (ANNOVA) Patients with Sensory neuronopathies (SNN) will be included. another peripheral neuropathy Diagnosis of sensitive neuronopathy - phase 1 Patients with small fiber neuropathy, chronic polyradiculoneuritis or other axonal neuropathy) will be included. another peripheral neuropathy Comparison of data with non-parametric test (ANNOVA) Patients with small fiber neuropathy, chronic polyradiculoneuritis or other axonal neuropathy) will be included. another peripheral neuropathy Comparison with Chi2 method Patients with small fiber neuropathy, chronic polyradiculoneuritis or other axonal neuropathy) will be included. Sensory neuronopathies (SNN) Comparison of data with parametric Test (T-test) Patients with Sensory neuronopathies (SNN) will be included. another peripheral neuropathy Comparison of data with parametric Test (T-test) Patients with small fiber neuropathy, chronic polyradiculoneuritis or other axonal neuropathy) will be included. dysimmune context without associated neuropathy. Diagnosis of sensitive neuronopathy - phase 1 Patient with dysimmune context without associated neuropathy will be included. Sensory neuronopathies (SNN) Diagnosis of sensitive neuronopathy - phase 2 Patients with Sensory neuronopathies (SNN) will be included. another peripheral neuropathy Diagnosis of sensitive neuronopathy - phase 2 Patients with small fiber neuropathy, chronic polyradiculoneuritis or other axonal neuropathy) will be included. dysimmune context without associated neuropathy. Comparison with Chi2 method Patient with dysimmune context without associated neuropathy will be included. dysimmune context without associated neuropathy. Diagnosis of sensitive neuronopathy - phase 2 Patient with dysimmune context without associated neuropathy will be included. dysimmune context without associated neuropathy. Comparison of data with non-parametric test (ANNOVA) Patient with dysimmune context without associated neuropathy will be included. dysimmune context without associated neuropathy. Comparison of data with parametric Test (T-test) Patient with dysimmune context without associated neuropathy will be included.
- Primary Outcome Measures
Name Time Method Sensitivity-specificity of Argonaute (AGO) antibodies for the diagnosis of sensory neuronopathies 2 Years Sensitivity-specificity of Argonaute (AGO) antibodies screening
- Secondary Outcome Measures
Name Time Method Comparison of data between patients with anti-AGO antibodies versus patients without anti-AGO antibodies 2 Years Clinical pattern of the neuropathy in patients with anti-AGO antibodies versus patients without anti-AGO antibodies
Trial Locations
- Locations (1)
CHU Saint-Etienne
🇫🇷Saint-Étienne, France